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Abstract
An extreme diversity of substrates and catalytic reactions of cytochrome P450 (P450) enzymes is considered to be
the consequence of evolutionary adaptation driven by different metabolic or environmental demands. Here we
report the presence of numerous natural variants of P450 BM3 (CYP102A1) within a species of Bacillus megaterium.
Extensive amino acid substitutions (up to 5% of the total 1049 amino acid residues) were identified from the
variants. Phylogenetic analyses suggest that this P450 gene evolve more rapidly than the rRNA gene locus. It was
found that key catalytic residues in the substrate channel and active site are retained. Although there were no
apparent variations in hydroxylation activity towards myristic acid (C14) and palmitic acid (C16), the hydroxylation
rates of lauric acid (C12) by the variants varied in the range of >25-fold. Interestingly, catalytic activities of the
variants are promiscuous towards non-natural substrates including human P450 substrates. It can be suggested
that CYP102A1 variants can acquire new catalytic activities through site-specific mutations distal to the active site.
Introduction
Cytochrome P450s (EC 1.14.14.1; P450 or CYP) are
remarkably diverse oxygenation catalysts that are found
throughout all classes of life. Although over 11,200 genes
of P450s have been found in archaea, bacteria, fungi,
plants, and animals (the Cytochrome P450 homepage,
http://drnelson.uthsc.edu/P450.statsfile.html), their evolu-
tion is not clear. An extreme diversity of substrates and
catalytic reactions is characteristic of P450s (Guengerich
2001) and is considered to be the consequence of evolu-
tionary adaptation driven by different metabolic or envir-
onmental demands in different organisms. Although most
bacterial P450s do not seem to be essential to basic meta-
bolism, they have important roles in the production of sec-
ondary metabolites and in detoxication (Kelly et al. 2005).
P450 BM3 (CYP102A1) from Bacillus megaterium is a
self-sufficient monooxygenase as it is fused to its redox
partner, an eukaryotic-like diflavin reductase. Interest-
ingly, sequence analysis for the P450 phylogenetic tree
suggested that the CYP102A1 clusters with the eukaryo-
tic P450s but not with other prokaryotic P450s (Lewis
et al. 1998). The natural substrates of CYP102A1 are
long chain fatty acids (C12 to C20), which are exclusively
hydroxylated at the subterminal positions (ω-1 to ω-3)
(Boddupalli et al. 1990). Furthermore, this enzyme
exhibits the highest catalytic activity ever detected
among P450 monooxygenase (Boddupalli et al. 1990).
Engineered CYP102A1 mutants derived by directed
evolution and rational design could oxidize several non-
natural substrates, including pharmaceuticals, short-
chain hydrocarbons, and environmental chemicals (Yun
et al. 2007; Stjernschantz et al. 2008; Seifert et al. 2009).
The potential of engineered CYP102A1 for biotechnolo-
gical applications has been recognized (Bernhardt 2006).
Recently, it was reported that CYP102A1 can be devel-
oped as a potentially versatile biocatalyst for the genera-
tion of human P450 drug metabolites (Yun et al. 2007;
Kim et al. 2009, 2010; Park et al. 2010; Sawayama et al.
2009; Whitehouse et al. 2009; Kim et al. 2011). Human
P450 enzymes are responsible for the metabolism of
about 75% of drugs used clinically (Williams et al. 2004;
Guengerich 2003). Human drug metabolites are very
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useful in evaluating a drug’s efficacy, toxicity, and phar-
macokinetics (Johnson et al. 2004; Atrakchi 2009;
Leclercq et al. 2009). They can also be used as starting
materials for drug candidates.
By using a systematic screening strategy, we found a
number of natural variants of CYP102A1. Although
there were no apparent variations in hydroxylation
activity towards myristic acid (C14) and palmitic acid
(C16), the oxidation rates of lauric acid (C12) by the
variants varied in the range of >25-fold. Some of the
natural variants showed catalytic promiscuity towards
non-natural substrates, particularly human P450 drug
substrates. This study shows that diverse mutations are
present in the gene of CYP102A1. Several specific resi-
dues for frequent mutations were found and the muta-
tional frequency of reductase domains was much higher




phosphate, glucose-6-phosphate dehydrogenase, δ-
aminolevulinic acid (δ-ALA), reduced b-nicotinamide
adenine dinucleotide phosphate (NADPH), fatty acids,
N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA), ferri-
cyanide, phenacetin, acetaminophen, chlorzoxazone,
coumarin, 7-ethoxycoumarin, and cytochrome c were
obtained from Sigma-Aldrich (St. Louis, MO).
Bacterial strains
Strains of B. megaterium used in this study were
obtained from Korean Culture Center of Microorgan-
isms (KCCM), Korean Collection for Type Cultures
(KCTC), American Type Microbiology (ATCC), and the
Institute of Fermentation, Osaka (IFO) (Table 1).
PCR and cloning of CYP102A1 natural variants
For DNA preparations, cells were grown in nutrient
broth. After overnight growth at 37°C, the cells were
centrifuged, washed, lysed, and enzymatically treated to
remove RNA and protein. The DNA preparation was
then treated with phenol-chloroform (50:50) and etha-
nol-precipitated. The purity was evaluated by measuring
UV absorbance. The variant genes from B. megaterium
were amplified by polymerase chain reaction (PCR)
using oligonucleotide primers and B. megaterium chro-
mosomal DNA template. First, PCR was carried out in a
50 μl reaction mixture containing template plasmid, for-
ward primer BamHI-F (5’- AGCGGATCCATGACAAT-
TAAAGAAATGCCTC-3’) and reverse primer SacI-R
(5’-ATCGAGCTCGTAGTTTGTAT-3’), dNTPs, and pfu
polymerase. The PCR was carried out for 30 cycles con-
sisting of 45 s of denaturation at 94°C, 45 s of annealing
at 52°C, and 90 s of extension at 72°C. Next, PCR was
carried out in a similar way by use of forward primer
SacI-F (5’-ATACAAACTACGAGCTCGAT-3’) and
reverse primer XhoI-R (5’-ATCCTCGAGTTACC-
CAGCCCACACGTC-3’). The PCR product was digested
with BamHI and SacI, and ligated into the pCW ori
expression vector that had previously digested with the
same restriction enzymes (Farinas et al. 2001). The
amplified genes were subsequently cloned into the
pCWBM3 BamHI/SacI vector at the BamHI/SacI
restriction sites.
Because PCR amplification could lead to the introduc-
tion of random mutations and cloning of PCR products
can fortuitously select the mutated sequences, all genes
of CYP102A1 variants were PCR amplified a second
time from genomic DNA and the sequences were
directly determined without prior cloning. Exactly the
Table 1 Bacillus megaterium strains used in this study,
and GenBank accession numbers for CYP102A1 variants,











KCCM 11745 102A1.1 (J04832)c FJ917385 FJ969781
IFO 12108 102A1.1 (J04832)c FJ969756 FJ969774
ATCC 14581 102A1.1 (J04832)c FJ969751 FJ969767
KCCM 41415 102A1.1 (J04832)c FJ969762 FJ969792
KCTC 3712 102A1.2 FJ899078 FJ969764 FJ969795
KCCM 12503 102A1.3 FJ899082 FJ969761 FJ969787
ATCC 15451 102A1.4 FJ899085 FJ969753 FJ969768
ATCC 10778 102A1.5 FJ899078 FJ969746 FJ969765
KCCM 11938 102A1.5 FJ899078 FJ969760 FJ969786
KCCM 11761 102A1.5 FJ899078 FJ969757 FJ969783
KCCM 11776 102A1.6 FJ899081 FJ969758 FJ969784
KCCM 11934 102A1.6 FJ899081 FJ969759 FJ969785
ATCC 14945 102A1.7 FJ899084 FJ969749 FJ969766
ATCC 21916 102A1.8 FJ899092 FJ969755 FJ969772
KCTC 2194 102A1.8 FJ859036 FJ969763 FJ969794
ATCC 19213 102A1.9 FJ899091 FJ969754 FJ969769
ATCC 12872 QM B1551d -e -e -e
aGenBank accession numbers (except J04832) were assigned to nucleotide
sequences determined in this study. The corresponding CYP102A1 variant
gene for each strain is listed.
bThe CYP102A1 variants were named based on the amino acid similarity
(Fig. 1a and Table 2).
cPreviously known as the nucleotide sequence of P450 BM3 (CYP102A1) from
B. megaterium (Ruettinger et al. 1989).
dGenetic Information regarding the CYP102A1 variant of B. megaterium QM
B1551 (ATCC 12872) was obtained from the Whole Genome Sequencing of
B. megaterium http://www.bios.niu.edu/b_megaterium/ and the variant was
designated as QM B1551. We only used its genetic information to compare to
those of other variants and did not study its biochemical and physical
properties.
eGenetic information of B. megaterium QM B1551 (ATCC 12872) regarding its
CYP102A1 variant, 16S rRNA, and ITS was obtained from the Whole Genome
Sequencing of B. megaterium http://www.bios.niu.edu/b_megaterium/.
Accession numbers were not provided.
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same variations as those shown in Table 1 were again
found, indicating that they were not artificially intro-
duced during the PCR amplification.
Sequencing and phylogenetic analysis of 16S rRNA and
ITS between 16s and 23s rRNA
The amplification of partial 16S rRNA genes was carried
out using the primers 9F (5’-GAGTTTGATCCTGGCT-
CAG-3’) and 1512R (5’-ACGGCTACCTTGTTAC-
GACTT-3’) (Ni et al. 2008). The amplification reaction
(25 μl) contained 50 ng DNA, 0.50 μM of each primer,
250 μM dNTPs, 1.5 mM MgCl2, and 1.25 U pfu poly-
merase in the buffer supplied by the manufacturer. The
PCR was carried out for initial denaturation at 95°C for
5 min, followed by 30 cycles consisting of 95°C for 45 s,
55°C for 45 s, and 72°C for 90 s and final extension at
72°C for 10 min. Amplification products (10 μl) were
electrophoresed in a 2% agarose gel and visualized
under UV light after staining with ethidium bromide.
Direct sequencing of the PCR products was performed
with an ABI BigDye terminator v3.1 sequencing Ready
Reaction kit.
One ITS region was amplified with primers 16S-F
(5’-AAGTCGGTGGAGTAACCGT-3’) and 23S-R
(5’- TGTTAGTCCCGTCCTTCAT-3’). PCR reactions
(25 μl) contained 50 ng DNA, 0.5 μM of each primer,
250 μM dNTPs, and 2.5 U Taq DNA polymerase in the
buffer supplied by the manufacturer. The PCR was carried
out for initial denaturation at 95°C for 15 min, followed by
35 cycles consisting of 95°C for 20 s, 52°C for 30 s, and
72°C for 60 s and final extension at 72°C for 3 min.
All sequencing procedures were repeated at least twice
for each strain. The 16S rRNA gene sequences and the
16S-23S rRNA intergenic spacers were compared to
sequences in the GenBank database using BLAST
(Altschul et al. 1990). The sequences were aligned by
using the CLUSTAL W program (Thompson et al. 1997).
Expression and purification of CYP102A1 natural variants
Plasmids were transformed into E. coli DH5aF’-IQ cell.
Overnight cultures (20 ml) grown in Luria-Bertani broth
with ampicillin (100 μg/ml) selection at 37°C were used
to inoculate a 250 ml culture of Terrific broth containing
100 μg/ml ampicillin, 1.0 mM thiamine, trace elements,
50 μM FeCl3, 1.0 mM MgCl2, and 2.5 mM (NH4)2SO.
Cells were grown at 37°C and 250 rpm to an OD600 of
between 0.6-0.8. Protein expression was induced by add-
ing 1.0 mM IPTG and 1.5 mM δ-ALA, and cultures were
grown at 28°C and 200 rpm for 50 h. The cells were har-
vested by centrifugation (15 min, 5,000 g, 4°C). The cell
pellet was resuspended in TES buffer [100 mM Tris-HCl
(pH 7.6), 500 mM sucrose, 0.5 mM EDTA] and lysed by
sonication (Sonicator, Heat Systems - Ultrasonic, Inc.).
After the lysate was centrifuged at 100,000 g (90 min,
4°C), the soluble cytosolic fraction was collected and
used for the activity assay. The cytosolic fraction was
dialyzed against 50 mM potassium phosphate buffer
(pH 7.4) and stored at -80°C until use. The P450 concen-
tration was determined by Fe2+-CO versus Fe2+ difference
spectra (Omura and Sato 1964).
Binding affinity of fatty acids to CYP102A1 variants
To determine dissociation constants (Kd values) of fatty
acids to the CYP102A1 variants, spectral binding titration
was performed for enzymes with saturated fatty acids
(lauric acid, myristic acid, and palmitic acid). The Kd
values of substrates to the CYP102A1 variants were
determined (at 23°C) by titrating 2.0 μM enzyme with the
ligand, in a total volume of 1.0 ml of 100 mM potassium
phosphate buffer (pH 7.4). The ligands were dissolved in
dimethylsulfoxide and final dimethylsulfoxide concentra-
tions were <1% (v/v). Absorbance increases at 390 nm
and decreases at 420 nm as the substrate concentration
increases (Lentz et al. 2001). The absorption difference
between 390 nm and 420 nm was plotted against the sub-
strate concentration (up to 1.0 mM) (Kim et al. 2008a, b).
The Kd values were determined from plots of induced
absorption changes versus ligand concentration. The data
were fitted using a standard hyperbolic function or
(where the Kd value was within 5-fold of the P450 con-
centration) a quadratic function for tight-binding ligands,
as described elsewhere (Girvan et al. 2010).
Assay of fatty acid hydroxylation by natural variants and
distribution of hydroxylated products
Metabolites were generated by incubation of 1.0 mM fatty
acids and P450 enzyme (100 pmol) in a 1.0 ml volume of
100 mM potassium phosphate (pH 7.4) for 20 min at 37°C
(Gustafsson et al. 2004). An aliquot of a NADPH-generat-
ing system was used to initiate reactions; final concentra-
tions were 10 mM glucose 6-phosphate, 0.5 mM NADP+,
and 1 IU/ml yeast glucose 6-phosphate dehydrogenase.
The reactions were terminated with a 2-fold excess of ice-
cold dichloromethane. After centrifugation of the reaction
mixture, the organic solvent was removed under a gentle
stream of nitrogen and the residue was dissolved in
BSTFA (50 μl) containing trimethylchorosilane (1%, v/v).
The solution was transferred to a glass vial and incubated
at 75°C for 20 min to yield trimethylsilylated products. To
determine the regioselectivity of hydroxylated products of
fatty acids at the ω-1, ω-2, and ω-3 positions, GC/MS ana-
lysis was carried out on a Shimadzu QP2010 (column
length, 30 m; internal diameter, 0.25 mm; film thickness,
0.1 μm), with electron-impact ionization. The GC oven
temperature was programmed for 1 min at 70°C followed
by an increase to 170°C at 25°C/min, to 200°C at 5°C/min,
and to 280°C at 20°C/min. The oven was finally held at
280°C for 5 min. The MS source and interface were
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maintained at 250 and 280°C, respectively, and a solvent
delay of 4 min was used. The mass spectra were col-
lected using electron ionization at 70 eV. The products
were identified by their characteristic mass fragmentation
patterns (Lentz et al. 2001). Turnover numbers of the
hydroxylation of fatty acids (lauric acid, myristic acid,
palmitic acid) by the variants of CYP102A1 were deter-
mined by a GC-FID detector (Shimadzu GC2010 with
FID detector). Essentially the same procedure was used
for the regioselectivity of the hydroxylated products of
fatty acid oxidation. The distribution of products was
based on the relative peak area of the chromatogram of
GC using hydroxylated products at ω position as
standards.
NADPH oxidation activities supported by natural variants
Reaction mixtures contained 1.0 mM fatty acid and
P450 enzyme (25 nM) in a 1 ml volume of 100 mM
potassium phosphate (pH 7.4). Initial rates of fatty
acid-induced NADPH oxidation were measured by
monitoring the absorption change at 340 nm (ε340 =
6,220 M-1cm-1) after NADPH was added at a concen-
tration of 200 μM. Rates of change in A340 absorbance
were converted into activity units (moles of NADPH
oxidized per minute per mole of enzyme) (Noble et al.
1999).
Enzymatic activities of reductase domains of natural
variants
For the reductase assay, two different types of reductase
substrates were used. One was a chemical substrate, fer-
ricyanide, and the other was cytochrome c, which is a
protein substrate, as described previously (Gustafsson
et al. 2004). Assays for reductase domain-dependent
electron transfer to exogenous electron acceptors (ferri-
cyanide or cytochrome c) were also performed at 37°C
in potassium phosphate (pH 7.4), with 2.5 nM enzyme,
200 μM NADPH, and electron acceptors (500 μM ferri-
cyanide; 100 μM cytochrome c). Ferricyanide reduction
was measured at 420 nm (ε420 = 1.02 mM
-1cm-1 for the
ferricyanide reduction product) and cytochrome c reduc-
tion was measured at 550 nm (ε550 = 21.0 mM
-1cm-1 for
the reduced cytochrome c).
Thermal stability
To analyze enzyme stability, enzymes (2.0 μM) were
incubated at different temperatures between 25 and
70°C for 20 min with subsequent cooling to 4°C in a
PCR thermocycler (Eiben et al. 2007). The stability of
the heme domain was calculated from heat-inactivation
curves of CO-binding difference spectra (Omura and
Sato 1964). The stability of the reductase domain was
calculated from the reduction of ferricyanide catalyzed
by reductase activity, as described above.
Catalytic activity assays towards human P450 substrates
Purified natural variants of CYP102A1 were character-
ized for human P450 enzyme activities using specific
substrates as summarized elsewhere (Yun et al. 2006):
phenacetin O-deethylation for human P450 1A2;
7-ethoxycoumarin (7-EC) O-deethylation for human
P450s 1A2, 2A6, and 2E1; 7-ethoxy-4-trifluoromethyl-
coumarin (7-EFC) O-deethylation for P450s 1A2 and
2B6; chlorzoxazone 6b-hydroxylation for P450 2E1;
coumarin 7-hydroxylation for P450 2A6.
Sequence analysis
DNA sequences of CYP102A1 variants, 16S rRNA
sequences, and the ITS alleles between 16S and 23S
rRNA genes obtained in this study were deposited in Gen-
Bank. The accession numbers are provided at Table 1.
Genetic information of B. megaterium QM B1551 (ATCC
12872) regarding the CYP102A1 variant, 16S rRNA, and
ITS was obtained from the homepage of Whole Genome
Sequencing of B. megaterium http://www.bios.niu.edu/
b_megaterium/.
The sequences were aligned using the MEGA 3.1
program (Molecular Evolutionary Genetic Analysis)
(http://www.megasoftware.net/mega_dos.html). The size
of CYP102A1 variants was 1,049 amino acids (Addi-
tional file 1). ITS (338 nucleotides) between 16S and
23S rRNA genes of B. megaterium was analyzed in this
study. Phylogenetic trees were conducted by the neigh-
bor-joining method using the MEGA 3.1 program. Boot-
strap analysis of the neighbor-joining data, using 1,000
resamplings, was carried out to evaluate the validity and
reliability of the tree topology.
Nucleotide sequence accession numbers
The nucleotide sequences determined in this study have
been deposited in the GenBank database (Table 1):
FJ859036, FJ899078, FJ899080 to FJ899082, FJ899084,
FJ899085, FJ899091, and FJ899092 for CYP102A1 var-
iants; FJ917385, FJ969746, FJ969749, FJ969751, and
FJ969753 to FJ969764 for 16S rRNA genes of B. mega-
terium; FJ969765 to FJ969769, FJ969772, FJ969774,
FJ969781, FJ969783 to FJ969787, FJ969792, FJ969794,
FJ969795 for ITS of 16S-23S rRNA genes of
B. megaterium.
Results
Natural variants of CYP102A1 within a species of B.
megaterium
Among 16 different strains of B. megaterium, 12 strains
have natural genetic variants of CYP102A1 (Table 1). As
some of them shared exactly the same DNA sequences,
there were ultimately nine different types of CYP102A1
natural variants (Figure 1a, Table 1 and 2), including four
previously reported variants (CYP102A1.1) (Ruettinger
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et al. 1989). Amino acid sequences of the CYP102A1 var-
iants showed more than 96% identity with CYP102A1.1
(Table 2 and Additional file 1). The amino acid differences
among the variants included 20 residues (CYP102A1.3,
20/1049, 1.9%) to 33 residues (CYP102A1.7, CYP102A1.8,
CYP102A1.9; 33/1049, 3.1%) among a total of 1,049 amino
acids (Table 2). Phylogenetic analyses of the amino acid
sequences of CYP102A1 variants showed that three var-
iants are closely related to CYP102A1.1 and five variants
are distinct from it (Figure 1a). Among the total 55
mutated amino acid residues, those located in the reduc-
tase domains (residues 474-1049) (45 of 55, 82%) occurred
at a much higher frequency than in heme domain
(residues 1-473) (10 of 55, 18%) (Table 2). Interestingly,
no substitutions in the amino acid residues of the active
site or substrate channel (Ravichandran et al. 1993; Li and
Poulos 1997) were seen among the 55 substitutions.
Phylogenic analysis of bacterial strains and natural
variants
The 16S rRNA gene has been the molecular standard in
studying evolutionary relationships among bacteria
(Woese et al. 1990). Although DNA sequences of the
16S rRNA genes of 16 B. megaterium strains are well
conserved (2 nucleotides are variable among a total of
1,394 nucleotides, 99.9% identity) (Figure 2a), the inter-
genic sequence (ITS_ alleles between 16S and 23S rRNA
genes, which reflect the evolution of the bacterial strains
(Gürtler 1999), showed 7 nucleotide variations among a
total of 338 nucleotides (98.8% identity) (Figure 2b).
Interestingly, the phylogenetic tree of ITS alleles was
quite different from that of CYP102A1 natural variants.
RNA analyses showed that the evolutionary profile of
CYP102A1 variants is different from that of host strains
(Figure 1).
Biochemical characterization of the natural variants
The biochemical properties of the variants were exam-
ined. All CYP102A1 variants could bind to saturated
fatty acids in the range of 12-16 carbons with a general
preference for long fatty acids (Figure 3a). The affinity
of the variants to the fatty acids was quite different from
that of CYP102A1.1 in the range of >50-fold for palmitic
acid. However, the variations were less than 5-fold for
lauric acid and myristic acid.
Although there were no apparent variations in hydro-
xylation activity towards myristic acid (C14) and palmitic
acid (C16), the oxidation rates of lauric acid (C12) by the
variants varied in the range of >25-fold (Figure 3b).
However, most of them did not show apparent changes
in regioselectivity towards fatty acids (Additional file 2).
For all fatty acids (C12, C14, C16) tested here, there were
no apparent variations of regioselectivity among a set of
CYP102A1 variants. CYP102A1 variants showed a pre-
ference for hydroxylation at the ω-1 position of lauric
acid, and myristic acid, and at the ω-2 position for pal-
mitic acid. Fatty acid-dependent NADPH oxidation rates
by the variants were also determined in the presence of
lauric, myristic, and palmitic acids (Kitazume et al.
2007) (Figure 3c). We could not find a direct correlation
between NADPH oxidation and product formation of
hydroxylated fatty acids.
The reductase activity towards ferricyanide was quite
dependent on the type of CYP102A1 variant (Additional
file 3). Variant CYP102A1.3 showed a 3-fold higher
activity than that of CYP102A1.1. In the case of cyto-
chrome c, variant CYP102A1.2 had the highest activity,
Figure 1 Summarized phylogeny of CYP102A1 natural variants
and intergenic sequence (ITS) alleles from B. megaterium strains.
(a) Phylogenetic analyses of CYP102A1 variants are based on the
amino acid substitutions (Table 2 and Fig. S1) and silent mutations are
excluded. Relative abundances are shown in parentheses. (b)
Phylogenetic analyses of B. megaterium strains, which express
CYP102A1, were based on the ITS gene sequences. The CYP102A1
variant expressed by each strain is shown as a number with an
asterisk in parentheses. Numbers on tree branches show the percent
bootstrap support for all branches important for interpretation. Nodes
with bootstrap values of 1,000 resamplings (expressed by
percentages) are indicated and the bar scales represent the
substitution of amino acids (a) or nucleotides (b) per site.
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Table 2 Sequence variations of CYP102A1 variantsa
CYP102A1 Variants
Mutated Amino acid Change of Nucleotide *2 *3 *4 *5 *6 *7 *8 *9 QMB1551
T2P 4A > C +
Heme domain V27I 79G > A + + + + + + +
A29T 85G > A + + + + + + +
V128I 382G > A + + + + + + + +
A136T 406G > A + + + + + + +
E208D 624A > C +
A222T 664G > A +
A296T 886G > A + +
D370E 1110C > A + +
K453Q 1357A > C + + + + + +
T464R 1392T > A + + + + + +
V471E 1413A > G + + + + + +
Reductase domain K474T 1422G > C + + + + + +
A475V 1424C > T + + + + + + + + +
Q513R 1539G > A +
R526P 1578C > T +
Q547E 1639C > G + + + + +
E559D 1677A > C + + +
L590F 1794C > A +
A591S 1771G > T +
D600E 1800C > A + + + + + +
V625L 1873G > T + + + + + +
D632N 1894G > A +
D638E 1914T > A + + + + +
K640A 1920A > T + + + + + +
A652S 1954G > T +
G661R 1981G > C + + + + +
T665A 1993A > G + + + + + + + + +
Q675K 2023C > A + + + + +
P676L 2027C > T + +
A679E 2036C > A + + +
E688A 2063A > C + + +
T716A 2146A > G + + + + +
A717T 2149G > A + + + + + +
A742G 2225C > G + + + + + + + + +
A783V 2348C > T + + + + +
A796T 2386G > A +
K814E 2440A > G + + + + + + + + +
I825M 2474A > G + + + + + +
R826S 2476C > A + +
R837H 2510G > A + +
E871N 2613G > T + + + + + + + +
I882V 2644A > G + + + + + + + + +
E888G 2663A > G + + + + + + + + +
D894G 2681A > G + + + + +
P895S 2683C > T + + +
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which was 3-fold higher than that of CYP102A1.1.
These variations seem to be related to the variations in
amino acid sequence.
Thermal stability of heme and reductase domains in the
natural variants
The thermal stability of the heme and reductase
domains was examined. The T50 value of the
CYP102A1.1 heme domain was 51°C and the variants
showed similar T50 values in the range of 51-55°C
(Figure 4). The T50 value of the CYP102A1.1 reductase
domain was 45°C and the T50 values of the variants’
reductase domains were in the range of 40-48°C.
CYP102A1.5 (T50, 48°C) showed the highest thermal sta-
bility among CYP102A1 variants. The thermal stabilities
of the reductase domains were much lower than those
of the heme domains of the CYP102A1 variants.
Catalytic promiscuity of the natural variants towards non-
natural substrates
It is known that wild-type and several mutants of
CYP102A1 could oxidize several human P450 substrates,
including pharmaceuticals (Yun et al. 2007). We exam-
ined the catalytic promiscuity of the CYP102A1 variants
towards non-natural substrates. They showed quite dis-
tinct catalytic activities towards typical human P450
substrates including drugs (Figure 5). CYP102A1.7 could
oxidize all human P450 substrates tested here. Although
the oxidation rates of the variants for all tested human
P450 substrates were fairly low (< 0.4 min-1), we
detected potential evidence for the evolvability of P450
catalytic activities. Low catalytic activity is an intrinsic
property of human P450 enzymes (Guengerich 2005).
This result indicates that the variants show catalytic
promiscuity towards non-natural substrates.
Discussion
The current study provides a glimpse into P450 diversity
in bacteria. Extensive diversity of P450 genes has been
found in bacteria, including a large set of strains of the
genus Bacillus (Porwal et al. 2009). As we begin to sur-
vey the variants of bacterial P450 enzymes through a
systematic approach with B. megaterium strains, there
are exciting opportunities for studying the catalytic cap-
abilities and the metabolic functions of the P450 mono-
oxygenase systems. This work shows the presence of a
number of P450 natural variants within a species of
B. megaterium. Multiple amino acid substitutions (up to
4 among 528 amino acids of Candida albicans) in a
fungal CYP51 (Kelly et al. 2005) and a large number of
alleles in human P450 (Human Cytochrome P450 Allele
Nomenclature Committee; http://www.cypalleles.ki.se/)
and human NADPH-P450 reductase (Huang et al. 2008)
genes were found. However, the diversity of a P450 gene
within a species is much lower in these species than in
B. megaterium CYP102A1.
Phylogenetic analysis suggests that CYP102A1 gene
could have evolved more rapidly than the rRNA gene
locus of the host strains under the selective pressures
of their environments. For example, B. megaterium
strains IFO 12108 (and KCCM 11745) and KCCM 12503
have exactly the same 16S rRNA genes and ITS, but
they express different variants of CYP102A1.1 and
CYP102A1.3, respectively (Figure 1b and 2). Given the
diversification of ITS alleles that accompanies the strain
evolution of B. megaterium, the distribution of CYP102A1
Table 2 Sequence variations of CYP102A1 variantsa (Continued)
G913S 2739C > T +
E948K 2842G > A + + + + +
S955N 2864G > A + + + + + + + + +
M968V 2904G > A + + + + + + + + +
Q971E 2911C > G +
M980V 2938A > G +
Q982R 2945A > G + +
A1009D 3026C > A + + + + + + + + +
D1020E 3060C > A + + + + + +
H1022Y 3066C > T + + +
Q1023K 3067C > G +
Q1023E 3067C > A + + +
G1040S 3118G > A +
aVariations of amino acids and nucleotides in CYP102A1 variants (*2~*9) relative to CYP102A1.1 (P450 BM3) (*1) are shown by a (+) mark. Information regarding
the CYP102A1 variant (designated as QMB1551) of B. megaterium QM B1551 (ATCC 12872) was obtained from the Whole Genome Sequencing of B. megaterium
http://www.bios.niu.edu/b_megaterium/. We only used its genetic information to compare to those of other variants. Blanks mean no change of amino acids or
nucleotides.
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variants should uniquely define particular clades (Figure 1
and 2).
The reductase domains of CYP102A1 variants are
more divergent than heme domains (Table 2 and Addi-
tional File 1). However, binding sites of heme, FMN,
and FAD, which are essential cofactors for oxidation
activities, are well conserved except for a few residues of
the FAD binding site of CYP102A1. Substitutions of
amino acids in reductase domains of CYP102A1 variants
occurred at high frequency (7.8% of total amino acid
residues). Mutations at the reductase domain may influ-
ence the monooxygenase activity of heme domain by
Figure 2 Comparison of distinct regions of 16S rRNA gene sequences and ITS from B. megaterium. Two and seven nucleotides were
variable among 1,394 and 338 nucleotides, respectively, of 16S rRNA (a) and ITS (b) genes of B. megaterium strains.
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controlling electron transfer process from reductase
domain to heme domain. The changes in activity due to
the mutations might give the organism a selective
advantage for the evolutionary adaptation driven by dif-
ferent metabolic or environmental demands. In addition,
the results of thermal stability (Figure 4) suggest that
the higher mutation rate of the CYP102A1 reductase
domain might affect the thermal stability of the reduc-
tase domains.
The occurrence of multiple amino acid substitutions
appears to be common in CYP102A1 natural variants,
although it is unclear as yet whether all identified muta-
tions are important for substrate affinity, thermal stability,
catalytic activities, and their promiscuity to non-natural
substrates. It is found that wild-type CYP102A1 can
catalyze the hydroxylation of chlorzoxazone, aniline and
p-nitrophenol, as well as the N-dealkylation of proprano-
lol and the dehydrogenation of nifedipine. These chemi-
cals are typical substrates of human P450s 2E1, 2D6, 1A2
and 3A4, which are the main drug-metabolizing enzymes.
The catalytic activities of P450 BM3 are either compar-
able or higher than those measured for the human
enzymes towards these smaller and non-physiological
substrates. These results suggested the possibility to
obtain fine chemicals including human drug metabolites
by using CYP102A1 (Yun et al. 2007 and references
therein). It should also be noted that highly active
mutants of CYP102A1.1 (P450 BM3), which were
obtained by directed evolution using random mutagen-
esis, towards non-natural substrates such as short-chain
Figure 3 Biochemical properties of natural variants . (a)
Dissociation constants (Kd values) of substrates (lauric acid, myristic
acid, and palmitic acid) to CYP102A1 natural variants. (b) Turnover
numbers of the hydroxylation of fatty acids (lauric acid, myristic acid,
palmitic acid) by the variants of CYP102A1. (c) Rates of fatty acid-
dependent NADPH oxidation by the variants of CYP102A1.
Figure 4 Thermal stability for each domain of CYP102A1
variants. Enzymes (2 μM) were incubated at different temperatures
between 25 and 70°C for 20 min with subsequent cooling to 4°C in
a PCR thermocycler. The stability of the heme domain was
calculated from heat-inactivation curves of CO-binding difference
spectra. The stability of the reductase domain was calculated from
the reduction of ferricyanide catalyzed by reductase activity.
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hydrocarbons (Peters et al. 2003), drugs (van Vugt-
Lussenburg et al. 2007), and xenobiotics (Whitehouse
et al. 2008) contained mutations that are not located in
the active site.
Substrate and catalytic promiscuities are believed to
be hallmark characteristics of primitive enzymes,
serving as evolutionary starting points from which
greater specificity is acquired following application of
selective pressures (Khersonsky et al. 2006). It was pro-
posed that the evolution of a new function is driven by
mutations that have little effect on the native function
but large effects on the promiscuous functions that
serve as the starting point (Aharoni et al. 2005). Here
we propose an alternative view of P450 evolution by
which bacterial P450 enzymes acquire a new catalytic
activity through mutations besides the crucial catalytic
residues of the substrate binding region, substrate
channel, and active site. This hypothesis may also pro-
vide clues to explain how P450 enzymes show broad
substrate specificity, a characteristic that is specific to
the P450 enzymes (Guengerich 2001). Catalytic pro-
miscuity of bacterial P450s, at least CYP102A1, seems
to be intrinsic to P450s, although the mechanisms by
which the mutations contribute to the new activity are
difficult to rationalize.
Here we report the presence of diverse natural var-
iants of CYP102A1 within a species of B. megaterium.
Phylogenetic analyses suggest that the CYP102A1 gene
evolves more rapidly than the rRNA gene locus. While
key catalytic residues in the substrate channel and active
site are retained, several specific residues for frequent
mutation were found. Although there were no apparent
variations in hydroxylation activity towards myristic acid
(C14) and palmitic acid (C16), the hydroxylation rates of
lauric acid (C12) by the variants varied in the range of
>25-fold. Furthermore, catalytic activities of the variants
are promiscuous towards non-natural substrates includ-
ing human P450 substrates. These results suggest that
bacterial P450 enzymes can acquire new catalytic activ-
ities through site-specific mutations distal to the active
site. As these natural variants show similar activities as
human P450 enzymes, they can be developed as indus-
trial enzymes for cost-effective and scalable production
of fine chemicals including drugs and their metabolites.
Combined with rational design and directed evolution,
the catalytic promiscuity of the self-sufficient CYP102A1
enzyme can be useful for extending their application in
several fields of biotechnology.
Additional material
Additional file 1: Amino acid sequence alignment of CYP102A1 and
its variants. CYP102A1 variants are arranged in order corresponding to
the molecular phylogeny (Figure 1a) as indicated by the simplified
schematic to the left of the amino acid alignment. Secondary structures
are shown below the CYP102A1 variant sequences: a-helices, red;
b-sheets, blue. Binding sites of cofactors are shown: heme (yellow), FMN
(dark blue), and FAD (gray).
Additional file 2: Distribution of hydroxylated products of fatty
acids by CYP102A1 variants. Regioselectivity of the hydroxylated
products of fatty acids at positions ω-1, ω-2, and ω-3 was determined.
Additional file 3: Enzymatic activities of the reductase domains of
CYP102A1 variants. Assays for reductase domain-dependent electron
transfer to exogenous electron acceptors (ferricyanide or cytochrome c)
were performed.
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